Cost-Effectiveness - diabetes
Situation:
-
Our client had a novel treatment for diabetes but no data on long-term clinical endpoints such as micro- and macrovascular complication rates.
-
As this was a new therapeutic class, the company needed to demonstrate budget-impact and cost-effectiveness to facilitate formulary decision-making amongst different HMOs.
IMS HEOR Approach:
-
IMS devised a two-tiered solution comprising a budget impact analysis and a long-term cost-effectiveness study.
-
Using the CORE Diabetes Model (developed by IMS HEOR staff) and available short-term clinical trial evidence, the long-term clinical and cost outcomes of our client's new treatment were projected over patient lifetimes.
-
A pharmacy-based budget impact model was developed for specialized use with smaller, local managed care organizations in the US market. Outcomes included expected number of patients, annual costs and compliance with medication.
Outcome:
-
Our client had a detailed analysis, which highlighted the survival benefit associated with the new drug and provided clear direction on its most efficient use within the target populations.
-
The client received formulary status for their product with a number of HMOs in the US.